BeiGene
BGNE
#934
Rank
HK$163.89 B
Marketcap
HK$1,473
Share price
-2.10%
Change (1 day)
-3.99%
Change (1 year)
BeiGene is a Chinese pharmaceutical company engaged in the R&D, and commercialization of molecularly-targeted, and immuno-oncology drugs for the treatment of cancer.

Earnings for BeiGene (BGNE)

Earnings in 2024 (TTM): -HK$6.93 Billion

According to BeiGene 's latest financial reports the company's current earnings are HK$3.09 Billion. In 2023 the company made an earning of -HK$9.41 Billion, an increase over its 2022 earnings that were of -HK$13.94 Billion. The earnings displayed on this page is the company's Pretax Income.

Earnings history for BeiGene from 2015 to 2024

Annual earnings

Year Earnings Change
2024 (TTM) -HK$6.93 Billion-26.31%
2023 -HK$9.41 Billion-32.52%
2022 -HK$13.94 Billion24.39%
2021 -HK$11.21 Billion-13.21%
2020 -HK$12.91 Billion72.69%
2019 -HK$7.48 Billion36.01%
2018 -HK$5.5 Billion616.83%
2017 -HK$0.77 Billion-15.24%
2016 -HK$0.91 Billion107.91%
2015 -HK$0.44 Billion

Earnings for similar companies or competitors

Company Earnings Earnings differencediff. Country
-HK$0.15 Billion-97.95%๐Ÿ‡บ๐Ÿ‡ธ USA
-HK$1.91 Billion-72.40%๐Ÿ‡บ๐Ÿ‡ธ USA